Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

Previous 2010 GuidanceCost of Sales (% of Total Revenue)

Unchanged

19% to 20%Selling, General and Admin. Expense*

$147 to $152

$145 to $150Research and Development Expense*

$147 to $152

$140 to $145Amortization and Contingent Consideration

$8 to $9

NAInterest Income

$4

$3 to $4 GAAP Net Income (Loss)**

$213 to $218

$(6) to $2Stock Compensation Expense

Unchanged

$37Non-GAAP Net Income

$28 to $33

$30 to $38*  Previous guidance did not include $5.0 million to $7.0 million in additional operating expenses associated with the acquisition of ZyStor Therapeutics, Inc.**  Includes $223.1 million resulting from reversal of deferred tax asset valuation allowanceAnticipated Upcoming Milestones4Q 2010: File IND for BMN-673 (PARP inhibitor)December 2010/ January 2011: Initiation of Phase 1 trial for BMN-701 for Pompe diseaseEarly 2011: Initiation of pivotal Phase III trial for Firdapse for LEMS in the U.S.Early 1Q 2011: Initiation of pivotal Phase III trial for GALNS for MPS IVA1Q 2011: Initiation of Phase Ib trial for BMN-673 (PARP inhibitor)Mid-2011: Final top-line results from PEG-PAL Phase II trial, including daily dosing and formulation studiesLate 2011: Availability of blood Phe monitor4Q 2011/1Q 2012: Initiation of Phase III PEG-PAL trial1Q 2012: Initiation of Phase I trial for BMN-111 for Achondroplasia1H 2012: NDA filing for Firdapse for LEMS in the U.S.4Q 2012: Approval of Firdapse for LEMS in the U.S.4Q 2012: U.S. and European filings for GALNS for MPS IVAResearch and Development ProgramsBioMarin continues to make significant investments in research and development to ensure continued growth of the company.  The current pipeline includes programs which are in various stages of development and are focused on treating a range of unmet medical needs.Advanced Programs

  • Firdapse: BioMarin expects to initiate a Phase III trial f
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin to Host a Research and Development Day on October 19th
    2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
    3. BioMarin to Present at the UBS Global Life Sciences Conference
    4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
    5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
    6. BioMarin Acquires ZyStor Therapeutics, Inc.
    7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
    8. BioMarin to Acquire LEAD Therapeutics
    9. BioMarin to Present at the Credit Suisse Healthcare Conference
    10. BioMarin Announces Third Quarter 2009 Financial Results
    11. BioMarin to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/30/2015)... LAKE, N.J. , May 30, 2015  Eisai Inc. ... 309), which showed that eribulin met the study,s primary endpoint ... or adipocytic sarcoma (ADI), two types of advanced soft tissue ... Annual Meeting of the American Society of Clinical Oncology ... the ASCO press conference on Saturday, May 30, and also ...
    (Date:5/30/2015)... May 30, 2015 Caris Life Sciences®, ... promise of precision medicine, today announced the presentation ... utility of Caris Molecular Intelligence®, the company,s panomic ... tumors that share histological features. In separate presentations ... of Clinical Oncology (ASCO) in Chicago, ...
    (Date:5/29/2015)... May 29, 2015 /CNW/ - Alliance Principle Ingredients/Neutrical Solutions ... the health product Galenic Health Ginger in Bentonite ... for adolescents and children. The product currently contains ... but within acceptable limits for adult dosing. ... digestive upset and disturbances. Alliance Principle Ingredients / ...
    Breaking Medicine Technology:Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 2Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 3Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 4Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 5Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features 6
    (Date:5/30/2015)... 2015 Promising clinical trial results presented ... Meeting 2015 show activity of the investigational anti-cancer agent ... against brain metastases and in another case in overall ... "I am thrilled to have been able to offer ... She didn't have any other great treatment options that ...
    (Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
    (Date:5/30/2015)... (PRWEB) May 30, 2015 NovaSure® endometrial ... lighten or stop periods, without the side effects ... can reduce or stop menstrual bleeding and works by ... (the part that causes the bleeding), with a quick ... suffer from heavy menstrual bleeding. Many women begin ...
    (Date:5/30/2015)... (PRWEB) May 30, 2015 The results ... crocidolite asbestos has a high potential to cause mesothelioma, ... full story now on the Surviving Mesothelioma website. ... of Occupational Medicine in Lodz, Poland found that, among ... workers between 1970 and 2012, all of them happened ...
    (Date:5/30/2015)... 30, 2015 One of the pervasive ... local healthcare options available. Often, the ruralness of a ... those in rural areas feeling the crunch of a ... or tired of paying high premiums and copays, ... with licensed physicians via the power of the internet. ...
    Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3
    ... at the place of work, according to a recent study ... between stress and poor health has also been identified by ... metabolic syndrome and stress among the 10,000 civil servants belonging ... who were studied, which also involves high blood pressure and ...
    ... Indian population. This disease is due to the inability of the ... be due to the inability of the body to maintain normal ... slight modification in the lifestyle can help the patients to tackle ... Hospital for Diabetes Research Center, Royapuram and was headed by the ...
    ... at the Max Planck Institute for Developmental Biology in Tübingen (now ... able to identify a // protein that seems to play a ... ,The protein called Staufen2, appears to play a ... if this protein was blocked out from a nerve cell, it ...
    ... Iceland-based Ossur hf., a global orthopaedics company, has acquired ... $ 38.4 million. ,The acquisition of Innovation ... acquisition// of Royce Medical in the U.S., and the ... With these acquisitions, and its 2003 acquisition of Generation ...
    ... Comprehensive Cancer Center – Arthur G. James Cancer Hospital ... tumor suppressor gene that could be of vital significance ... well as lung cancer. //Their study shows that activating ... the aforementioned cancers. ,The gene, called TCF21 is ...
    ... available to Canadians from supermarkets and corner stores as a ... from making crystal meth. //The supermarkets and drug stores which ... which will come into force from 10 April 2006. Only ... are of the single ingredient category. This is inclusive of ...
    Cached Medicine News:Health News:Protein Found to Be Essential For Maintaining Nerve Health 2Health News:Ossur Acquires the U.S. Orthopaedics Company 2Health News:Unusual Tumor-Suppressor Gene Switches Off in Lung Cancer 2
    Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
    ... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
    ... The Vitek is a completely automated instrument ... of 2 - 6 hour same day ... quality control module. It is used for ... and urine screening and has a complete ...
    IDS Rapid One, a microbial identification system....
    Medicine Products: